Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00270816
Status:
COMPLETED
Last Update Posted:
2018-12-19
First Post:
2005-12-27
Brief Title:
Interferon ß-1b Treatment by Cyclical Administration
Sponsor:
S Andrea Hospital
Organization:
S Andrea Hospital
Study Overview
Official Title:
Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The therapy with Interferon-ß-1b reduces the inflammatory component of multiple sclerosis with positive effects on the disease course The 8 MUI dose at alternate days is kept constant for years About 13 of patients suspend treatment by three years due to side effects or suspected or accepted ineffectiveness The main objective of the study is to verify the safety and effectiveness of a cyclical administration a month of suspension after two of treatment from the beginning of treatment There is the possibility that a scheme envisaging therapy free intervals can reduce the onset of negative feedbacks antagonising the drug therapeutic effect compared to the standard administration protocol This might also result in an increase of the drug effectiveness andor in a longer duration of effectiveness itself Finally cyclical administration allows patients to spend actual periods of therapeutic vacation with positive psychological effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None